Study results published in the journal Cell suggest that a single-cell analysis method could identify multiple antibodies from patients with COVID-19 that could neutralise the novel coronavirus, as reported The Financial Express on Monday.
The scientists used high-throughput single-cell genome sequencing to identify the antibodies from convalescent plasma.
The researchers demonstrated a rapid and efficient single-cell genome sequencing method to narrow down on specific B cells, and identify SARS-CoV-2 neutralising antibodies from convalescent COVID-19 patients.
"We showed that high-throughput single-cell sequencing could lead to the identification of highly potent neutralizing mAbs that have strong therapeutic and prophylactic efficacy," the researchers said.
The antibodies were tested in genetically engineered mice expressing the human form of the receptor ACE2, which is the gateway protein used by the novel coronavirus to enter cells, and the researchers found that some of the antibodies neutralised the virus.
"The potent neutralising antibodies we identified may provide an effective therapeutic and prophylactic solution, evidenced by the results on hACE2 transgenic mice," the researchers said, adding that clinical trials using the antibodies are currently underway.
To read more NewsPoints articles, click here.